Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $496.6, down 4.91% amid market reaction to its $10 billion acquisition of Crinetics Pharmaceuticals. The stock maintains strong fundamentals with a 29.58 P/E ratio and 35.51% net income margin, supported by consistent earnings beats. Technical analysis shows a bullish trend with key support at $491 and resistance at $526. Recent news highlights strategic growth through M&A, positioning Vertex for expanded product portfolio and revenue potential.
Outlook remains positive with analyst consensus at Buy (84%) and a $526.50 price target, though integration risks from the Crinetics deal and valuation premiums pose near-term volatility. Long-term growth drivers include pipeline expansion and market dominance in specialty therapeutics, balanced by execution and regulatory hurdles.
Read full analysis

Key Stats

  • Market Cap
    $126.01B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $120.75B
  • Div Yield
    -
  • Trading Activity
    -
$494.12
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Global wax market to reach $16.65B by 2035 driven by packaging, cosmetics, and industrial demand.

The global wax market, valued at $11.26 billion in 2025, is projected to grow to $16.65 billion by 2035 at a CAGR of 3.99%. Growth is fueled by rising demand in packaging, cosmetics, candle making, adhesives, and industrial uses, with natural waxes l...

Market News
1 hour ago
Sns Insider
Bullish
news icon
pluang ai news

Basel Medical regains Nasdaq compliance after share price recovers above $1.00

Basel Medical Group Ltd announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 10 consecutive business days ending July 7, 2026. The company was previously notified in January 2026...

Market News
1 hour ago
Na
Bullish
news icon
pluang ai news

Backpack launches first 24/7 market for real U.S. equities for global investors.

Backpack has introduced the first-ever 24/7 trading platform for real U.S. equities, allowing international investors to buy and sell stocks like SpaceX, Micron, and SanDisk around the clock. Unlike synthetic derivatives, these are actual equities wi...

Market News
1 hour ago
Na
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

Key Stats

  • Market Cap
    $126.01B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $529.59
  • 52W Low
    $366.54
  • Typical Hold Time
    -
  • Enterprise Value
    $120.75B
  • Div Yield
    -
  • Trading Activity
    -
$494.12
52W Low: $366.54
08 Aug 2025
52W High: $529.59
06 Jul 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $529.59, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!